Sign up for a free trial and join thousands of other leading professionals. Click here to start!

Acute Myeloid Leukemia News

Home | Index > Health > Cancer > Acute Myeloid Leukemia

TAKE THIS POLL
According to the White House, 650,000 jobs were created or saved by $150 billion in stimulus funds. Was it money well spent? (Oct. 30, 2009) Yes. No. Don't know.

Sort by: relevance (24 hours) relevance date

First report of using radiolabeled antibodies and stem cell transplantation to successfully treat advanced leukemia 7 Nov 2009 19:16 GMT
... options. All fifty-eight patients, with a median age of 63 and all with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome - a pre-leukemic condition - saw their blood cancers go ...
Advanced Leukemia Successfully Treated With First Use Of Antibody And Stem Cell Transplantation 7 Nov 2009 08:37 GMT
... options. All fifty-eight patients, with a median age of 63 and all with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome - a pre-leukemic condition - saw their blood go into ...
Clarendon Hills Scouts plan bone marrow drive 7 Nov 2009 03:40 GMT
... Clarendon Hills resident and local speech therapy teacher is fighting her second bout with acute myeloid leukemia, a type of cancer that begins inside a person's bone marrow and kills white ...
Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 5 Nov 2009 13:42 GMT
... Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia SOUTH SAN FRANCISCO, ...
Oncogenic italic>RAS/italic> Enables DNA Damage- and p53-Dependent Differentiation of Acute Myeloid Leukemia Cells in Response to Chemotherapy 5 Nov 2009 15:18 GMT
... / Oncogenic Enables DNA Damage- and p53-Dependent Differentiation of Acute Myeloid Leukemia Cells in Response to Chemotherapy Oncogenic Enables DNA Damage- and p53-Dependent Differentiation of Acute ...

Cyclacel Pharmaceuticals Reports Survival Data From Phase 2 Sapacitabine Study in Elderly Patients With Acute Myeloid Leukemia 6 Nov 2009 00:03 GMT
... Cyclacel Pharmaceuticals Reports Survival Data From Phase 2 Sapacitabine Study in Elderly Patients With Acute Myeloid Leukemia BERKELEY HEIGHTS, N.J., Oct. 28, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ...
Sunesis Completes Enrollment of Voreloxin REVEAL-1 Trial in Acute Myeloid Leukemia 2 Nov 2009 21:31 GMT
... Sunesis Completes Enrollment of Voreloxin REVEAL-1 Trial in Acute Myeloid Leukemia SOUTH SAN FRANCISCO, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. ( ) today ...
Sunesis' voreloxin earns FDA Orphan Drug designation for acute myeloid leukemia 6 Nov 2009 12:17 GMT
... and Drug Administration (FDA) has granted voreloxin Orphan Drug designation for the treatment of acute myeloid leukemia (AML). The company is currently conducting two Phase II studies of voreloxin in AML ...
www.StockMarketingInc.com: Wake Up People!! Sign Up For The Free Newsletter!! WZE: "Wizzard Media Launches 24 New iPhone Apps" 5 Nov 2009 17:41 GMT
... its R&D pipeline, please visit www.intermune.com. Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia SOUTH SAN FRANCISCO, Calif., Nov 05, 2009 -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today ...
ARIAD's AP24534 Featured in Cancer Cell Publication as a Potential First-in-Class Pan BCR-ABL Inhibitor 2 Nov 2009 17:14 GMT
... is now in a Phase 1 dose-escalating clinical trial in patients with refractory CML, acute myeloid leukemia (AML) and other hematological malignancies. “These data support the ongoing clinical study of AP24534 ...

Not satisfied with this news section? Make your own with the Newsletter Manager or try our other media monitoring services.

ARIAD's AP24534 Featured in Cancer Cell Publication as a Potential First-in-Class Pan BCR-ABL Inhibitor(Graphic: Business Wire) 2 Nov 2009 18:34 GMT
... is now in a Phase 1 dose-escalating clinical trial in patients with refractory CML, acute myeloid leukemia (AML) and other hematological malignancies. 'These data support the ongoing clinical study of AP24534 ...
Cancer Cell publishes a paper on ARIAD Pharmaceuticals' Pan-BCR-ABL inhibitor 3 Nov 2009 05:53 GMT
... is now in a Phase 1 dose-escalating clinical trial in patients with refractory CML, acute myeloid leukemia (AML) and other hematological malignancies. “These data support the ongoing clinical study of AP24534 ...
Two Genes Cooperate To Cause Aggressive Leukemia 3 Nov 2009 17:54 GMT
... Birgitta Swolin and Martin O. Bergö. NF1 deficiency co-operates with oncogenic K-RAS to induced acute myeloid leukemia in mice ...
EpiCept Corporation Names Bernard Tyrrell as Senior Vice President, Sales and Marketing (BIZ) 6 Nov 2009 05:30 GMT
... excited to begin my work by helping to commercialize Ceplene(R) for people suffering from Acute Myeloid Leukemia (AML) in first remission. I am looking forward to working with the team and ...
EpiCept Corporation Names Bernard Tyrrell as Senior Vice President, Sales and Marketing 6 Nov 2009 05:31 GMT
... excited to begin my work by helping to commercialize Ceplene(R) for people suffering from Acute Myeloid Leukemia (AML) in first remission. I am looking forward to working with the EpiCept team ...
Cyclacel Pharmaceuticals Announces Third Quarter 2009 Financial Results 3 Nov 2009 21:32 GMT
... study of sapacitabine as a treatment for elderly patients aged 70 and older with acute myeloid leukemia (AML) provides a strong rationale supporting the continued development of this novel agent," said ...
2 genes cooperate to cause aggressive leukemia 3 Nov 2009 15:31 GMT
... 342 7858, Title of the article: NF1 deficiency co-operates with oncogenic K-RAS to induced acute myeloid leukemia in mice Authors: Briony A. Cutts, Anna-Karin M. Sjgren, Karin M.E. Andersson, Annika M. ...
Families, DOD spar over dangers of burn pit smoke 5 Nov 2009 19:40 GMT
... sons Nate and Aaron). Bumpus died in August 2008 after a two-year battle with Acute Myeloid Leukemia, a rare and aggressive cancer his family believes was caused by exposure to burn ...
New therapy shows promise in treating advanced leukemia 6 Nov 2009 09:46 GMT
... a group of leukemia and pre-leukemia patients, The study showed that patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome - a pre-leukemic condition - experienced a remission with the ...
First use of antibody and stem cell transplantation to successfully treat advanced leukemia 5 Nov 2009 17:52 GMT
... options. All fifty-eight patients, with a median age of 63 and all with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome � a pre-leukemic condition � saw their blood cancers go ...

THESE STORIES ARE NOT PUBLISHED BY IPD GROUP, INC. AND THESE LINKS WILL TAKE YOU TO OTHER WEBSITES. SOME OF THESE WEBSITES REQUIRE THEIR OWN REGISTRATION TO READ THEIR STORIES. PLEASE READ THE DISCLAIMER FOR MORE DETAILS. >>>

Successful leukemia treatment with a radiolabeled antibody followed by stem cell transplant 6 Nov 2009 08:13 GMT
... options. All fifty-eight patients, with a median age of 63 and all with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome - a pre-leukemic condition - saw their blood cancers go ...
BUYINS.NET: SSS, XNPT, EBS, ARIA, OPTV, BGFV Expected To Be Lower Leading Up To Next Earnings Releases 2 Nov 2009 16:37 GMT
... and AP24534, a multi-targeted kinase inhibitor for the treatment of chronic myeloid leukemia (CML), acute myeloid leukemia (AML), and other hematological cancers. ARIAD conducts Phase 3 clinical trials of oral deforolimus ...
SSS, XNPT, EBS, ARIA, OPTV, BGFV Expected To Be Lower Leading Up To Next Earnings Releases 2 Nov 2009 17:56 GMT
... and AP24534, a multi-targeted kinase inhibitor for the treatment of chronic myeloid leukemia (CML), acute myeloid leukemia (AML), and other hematological cancers. ARIAD conducts Phase 3 clinical trials of oral deforolimus ...
Lifetime of giving 6 Nov 2009 02:53 GMT
... professor Bo Green has donated gallons of his blood. But after being diagnosed with acute myeloid leukemia, he has found himself on the receiving end of blood donations. With his immune ...
Data for EntreMed's ENMD-2076 to Be Presented at the Upcoming AACR-NCI-EORTC Conference 3 Nov 2009 12:32 GMT
... No.: A106, "A Phase 1 study of ENMD-2076 in patients with relapsed or refractory acute myeloid leukemia (AML)," Halls C-D, 2nd floor. Monday, November 16, 2009 - 12:30 p.m. - 2:30 ...